Drug Profile
Samidorphan
Alternative Names: ALKS 33; RDC-0313; RDC-0313-00Latest Information Update: 03 Jun 2021
Price :
$50
*
At a glance
- Originator Rensselaer Polytechnic Institute
- Developer Alkermes; Alkermes plc
- Class Amides; Cyclopropanes; Drug withdrawal therapies; Morphinans; Small molecules
- Mechanism of Action Opioid mu receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alcoholism; CNS disorders; Eating disorders; Substance-related disorders
Most Recent Events
- 07 Nov 2019 Ad-hoc task: Indication change from Drug abuse to Substance-related disorders - replaced the indication Drug abuse with Substance-related disorders in the Intro and HEs
- 17 Dec 2015 No development reported - Phase-I for CNS disorders (In volunteers) in USA (PO)
- 17 Dec 2015 No development reported - Phase-I for Substance-related disorders (In volunteers) in USA (PO)